SEC Tracker
Get the app

NeuroPace NPCE

NeuroPace FY 2021: revenue $45.2M; diluted EPS −$2.17

Form
10-K
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers NeuroPace reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$45.2MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Net income−$36.1MNo year-earlier figure tagged10-K income statement, on EDGAR
  3. Diluted EPS−$2.17No year-earlier figure tagged10-K income statement, on EDGAR
  4. Cash and cash equivalents$19.2MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  5. Cash from operations−$24.6MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when NeuroPace files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. ClearPoint Neuro CLPT public float $328M, Jun 30, 2025
  2. Outset Medical OM public float $335M, Jun 30, 2025
  3. SS Innovations International SSII public float $270M, Jun 30, 2025
  4. EBR Systems EBRCZ public float $351M, Jun 30, 2025
  5. Treace Medical Concepts TMCI public float $266M, Jun 30, 2025